Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics.
Le VH, Inai M, Williams RM, Kan T.
Nat Prod Rep · research-article; review; journal article · DOI 10.1039/c4np00051j PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för trabectedin. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
26 hitsAnti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models.
Peraldo-Neia C, Cavalloni G, Soster M, Gammaitoni L, Marchiò S, Sassi F, Trusolino L, Bertotti A, Medico E, Capussotti L, Aglietta M, Leone F.
BMC Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1471-2407-14-918A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.
Leporini C, Patanè M, Saullo F, Rende P, Gallelli L, Di Paola ED, Toscano R, Lucia M, Rossi M, De Sarro G, Russo E.
BioDrugs · research support, non-u.s. gov't; review; journal article · DOI 10.1007/s40259-014-0100-7The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
Schack LH, Mouritsen LS, Elowsson C, Krarup-Hansen A, Safwat A.
Acta Oncol · multicenter study; journal article · DOI 10.3109/0284186x.2014.958530Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Machiels JP, Staddon A, Herremans C, Keung C, Bernard A, Phelps C, Khokhar NZ, Knoblauch R, Parekh TV, Dirix L, Sharma S.
Cancer Chemother Pharmacol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1007/s00280-014-2554-1Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.
Mascilini F, Amadio G, Di Stefano MG, Ludovisi M, Di Legge A, Conte C, De Vincenzo R, Ricci C, Masciullo V, Salutari V, Scambia G, Ferrandina G.
Onco Targets Ther · review-article; review; journal article · DOI 10.2147/ott.s51550Third-line trabectedin for a metastatic desmoplastic small round cell tumour treated with multimodal therapy.
Brunetti AE, Delcuratolo S, Lorusso V, Palermo L, Di Giorgio A, Pisconti S, Silvestris N.
Anticancer Res · research support, non-u.s. gov't; journal article; case reportsAntiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.
Dossi R, Frapolli R, Di Giandomenico S, Paracchini L, Bozzi F, Brich S, Castiglioni V, Borsotti P, Belotti D, Uboldi S, Sanfilippo R, Erba E, Giavazzi R, Marchini S, Pilotti S, D'Incalci M, Taraboletti G.
Int J Cancer · research support, non-u.s. gov't; journal article · DOI 10.1002/ijc.29023Trabectedin: novel insights in the treatment of advanced sarcoma.
Lopez JP, Gajdos C, Elias A.
Curr Oncol Rep · review; journal article · DOI 10.1007/s11912-014-0387-zCombination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Kawano M, Mabuchi S, Kishimoto T, Hisamatsu T, Matsumoto Y, Sasano T, Takahashi R, Sawada K, Takahashi K, Takahashi T, Hamasaki T, Kimura T.
Int J Gynecol Cancer · research support, non-u.s. gov't; journal article · DOI 10.1097/igc.0000000000000143Trabectedin in soft tissue sarcomas.
Brodowicz T.
Future Oncol · research support, non-u.s. gov't; review; journal article · DOI 10.2217/fon.14.117Going further in the knowledge of Yondelis®; what's new in daily clinical practice?
Blay JY.
Future Oncol · research support, non-u.s. gov't; review; journal article · DOI 10.2217/fon.14.115Prolonged disease stability with trabectedin in two monorenal patients with retroperitoneal sarcoma.
Bruder F, Massa D, Barca M, Contu V, Airoldi M, Crova A.
Tumori · research support, non-u.s. gov't; journal article; case reports · DOI 10.1700/1578.17230Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.
D'Incalci M, Badri N, Galmarini CM, Allavena P.
Br J Cancer · review-article; review; journal article · DOI 10.1038/bjc.2014.149Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma.
Ueda T, Kakunaga S, Ando M, Yonemori K, Sugiura H, Yamada K, Kawai A.
Invest New Drugs · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1007/s10637-014-0094-5Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study.
Delaloge S, Wolp-Diniz R, Byrski T, Blum JL, Gonçalves A, Campone M, Lardelli P, Kahatt C, Nieto A, Cullell-Young M, Lubinski J.
Ann Oncol · clinical trial, phase ii; research support, non-u.s. gov't; journal article · DOI 10.1093/annonc/mdu134Quantification of trabectedin in human plasma: validation of a high-performance liquid chromatography-mass spectrometry method and its application in a clinical pharmacokinetic study.
Zangarini M, Ceriani L, Sala F, Marangon E, Bagnati R, D'Incalci M, Grosso F, Zucchetti M.
J Pharm Biomed Anal · validation study; journal article · DOI 10.1016/j.jpba.2014.02.018Anti-angiogenic effects of trabectedin (Yondelis; ET-743) on human breast cancer cells.
Atmaca H, Uzunoglu S.
Eur Cytokine Netw · research support, non-u.s. gov't; journal article · DOI 10.1684/ecn.2014.0347Trabectedin in Advanced High-Grade Uterine Leiomyosarcoma: A Case Report Illustrating the Value of (18)FDG-PET-CT in Assessing Treatment Response.
Payne MJ, Macpherson RE, Bradley KM, Hassan AB.
Case Rep Oncol · journal article; case reports; case-report · DOI 10.1159/000355224Tumor calcification: a new response pattern of myxoid liposarcoma to trabectedin.
Turpin A, Taieb S, Penel N.
Case Rep Oncol · journal article; case reports; case-report · DOI 10.1159/000360575Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
Grohar PJ, Segars LE, Yeung C, Pommier Y, D'Incalci M, Mendoza A, Helman LJ.
Clin Cancer Res · research support, n.i.h., intramural; research support, non-u.s. gov't; research-article; journal article · DOI 10.1158/1078-0432.ccr-13-0901Total synthesis of ecteinascidin 743.
Kawagishi F, Toma T, Inui T, Yokoshima S, Fukuyama T.
J Am Chem Soc · research support, non-u.s. gov't; journal article · DOI 10.1021/ja408034xThe impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin.
D'Angelo D, Borbone E, Palmieri D, Uboldi S, Esposito F, Frapolli R, Pacelli R, D'Incalci M, Fusco A.
Eur J Cancer · research support, non-u.s. gov't; evaluation study; journal article · DOI 10.1016/j.ejca.2012.10.014Trabectedin: safety and efficacy in the treatment of advanced sarcoma.
Gajdos C, Elias A.
Clin Med Insights Oncol · review-article; journal article · DOI 10.4137/cmo.s4907Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, Khan J, Helman LJ.
Neoplasia · research support, n.i.h., intramural; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1593/neo.101202Trabectedin and its potential in the treatment of soft tissue sarcoma.
Cassier PA, Dufresne A, Blay JY, Fayette J.
Ther Clin Risk Manag · review-article; journal article · DOI 10.2147/tcrm.s1174